Liposorber

11/14/2025

🫀 sure did not disappoint! From immersive experiences to puppy snuggles and connecting with physicians, new and current — we had a fantastic conference!

Thanks to all who stopped by our booth and to our dedicated team, who showed up ready to engage each and every day! 🫶🏻

11/14/2025

IMPORTANT: Critical Safety Check Before Your First LIPOSORBER® Treatment.

Prior to starting therapy, it is essential to discuss all current medications and dietary restrictions with your treating physician.

SAFETY ALERT: ACE inhibitors (a class of blood pressure medications) must not be taken in combination with LIPOSORBER, as they are contraindicated and may lead to serious adverse effects. If you are currently taking an ACE inhibitor, please consult your physician well in advance of your first LIPOSORBER session to discuss switching to an alternative antihypertensive medication, such as an ARB, if appropriate. Your health and safety are our top priority.For LIPOSORBER Indications for Use and other safety information, please visit: https://liposorber.com/liposorber-safety-info/

11/11/2025

When diet and maximum drug therapies fail, LIPOSORBER provides hope. 🙏 Our extracorporeal therapy is designed to remove harmful LDL-C and Lp(a) from the blood, offering patients a vital treatment path for life-altering conditions.

It is FDA-approved for treating Familial Hypercholesterolemia (FH) and is available under a Humanitarian Device Exemption (HDE) for Focal Segmental Glomerulosclerosis (FSGS)

With over 600,000 treatments performed worldwide, we are committed to delivering excellence and peace of mind. Talk to your doctor to see if LIPOSORBER is right for you.
https://liposorber.com



For LIPOSORBER Indications for Use and other safety information, please visit: https://liposorber.com/liposorber-safety-info/

11/07/2025

🚨 ATTENTION PROVIDERS: A key update is coming to ICD-10-CM coding for Familial Hypercholesterolemia (FH). Effective October 1, 2025, code E78.01 has been retired. This transition reflects a necessary move toward greater specificity in diagnosis and treatment planning. Please ensure your documentation reflects these new codes for precise patient care:

E78.010 – Homozygous FH (HoFH)

E78.011 – Heterozygous FH (HeFH)

E78.019 – FH, unspecified

Stay ahead of the curve in specialized lipid management! 🩺
https://liposorber.com



For LIPOSORBER Indications for Use and other safety information, please visit: https://liposorber.com/liposorber-safety-info/

11/05/2025

Important Research Update! 💡 We are proud to share our recent peer-review collaborative paper focusing on the critical link between Peripheral Artery Disease (PAD) and elevated Lipoprotein(a) [Lp(a)]. Understanding this connection is vital for managing patients who fail diet and maximum drug therapies. At LIPOSORBER, we are committed to advancing the science behind specialized lipoprotein apheresis to offer hope and better outcomes. Learn more about the implications of elevated Lp(a) in PAD today!

https://liposorber.com/



For LIPOSORBER Indications for Use and other safety information, please visit: https://liposorber.com/liposorber-safety-info/

LIPOSORBER® is the FDA-approved treatment that works to help alleviate complications due to cardiovascular and kidney diseases. Visit our website for more info.

11/03/2025

Let the countdown begin! 🥳 Join us at the American Heart Association (AHA) Scientific Session in New Orleans! The future of cardiovascular science starts here, and we're ready to connect. Visit the LIPOSORBER team at Booth #3902 from November 8-10. Stop by to learn how our extracorporeal therapy is helping patients with FH and FSGS attain their therapeutic targets when diet and maximum drug therapies fail. See you there! 👋

https://professional.heart.org/en/meetings/scientific-sessions/registration



For LIPOSORBER Indications for Use and other safety information, please visit: https://liposorber.com/liposorber-safety-info/

10/30/2025

October Highlights: New Pediatric Video Inside! - https://mailchi.mp/kaneka/liposorbernewsletter-mar2025-16889232

10/14/2025

Effective October 2025, ICD-10-CM code E78.01 (Familial hypercholesterolemia) has been deleted and replaced with three new, more specific codes to better reflect clinical distinctions - https://mailchi.mp/kaneka/liposorbernewsletter-mar2025-16889193

09/30/2025

Spotlight on September: This month we helped raise awareness for PAD and celebrated the impact of apheresis in patient care. Check out the highlights in our latest newsletter! https://mailchi.mp/kaneka/liposorbernewsletter-mar2025-16889133

09/24/2025

🩺 Check out how Lipoprotein Apheresis (LIPOSORBER) greatly impacted a patient with no other treatment options at Cedars-Sinai, resulting in improved symptoms and wound healing.

Reference: Suzuki, K, et al. Lipoprotein Apheresis Therapy for “No-Option” Peripheral Arterial Disease Patients. Poster presented at DFCon 2024, Cedars-Sinai Medical Center, Los Angeles, CA.

For LIPOSORBER Indications for Use and other safety information, please visit: liposorber.com/liposorber-safety-info

09/18/2025

A study of 113 patients with elevated Lp(a) and/or LDL-C—major cardiovascular risk factors—found that lipoprotein apheresis (LIPOSORBER) significantly reduced cardiovascular events over 2 years:
✅ 75% fewer coronary artery events
✅ 71% fewer peripheral artery events
✅ 60% fewer cerebrovascular events

These results highlight LIPOSORBER’s powerful role in reducing cardiovascular risks when traditional therapies fall short.

Reference: Schatz, U., S. Tselmin, G. Müller, et al. "Most Significant Reduction of Cardiovascular Events in Patients Undergoing Lipoprotein Apheresis Due to Raised Lp(a) Levels – A Multicenter Observational Study." Atheroscler Suppl, vol. 30, 2017, pp. 246-252, doi:10.1016/j.atherosclerosissup.2017.05.047.

For LIPOSORBER Indications for Use and other safety information, please visit: liposorber.com/liposorber-safety-info

09/16/2025

🌟 Apheresis Awareness Day | September 16 🌟
LIPOSORBER is more than a apheresis machine — it can be a lifeline for patients with challenging conditions like FH and FSGS. And it’s the nurses who make it all possible, guiding patients through their journey with care and expertise.

To every nurse who uses LIPOSORBER to help patients feel better, live better, and hope more — thank you. Your impact is immeasurable.

For LIPOSORBER indications for use and safety information, please visit: liposorber.com/liposorber-safety-info